Imfinzi (Durvalumab)

Durvalumab is a cancer medicine used for several cancers, including lung, liver, bladder and stomach cancer. It is an immunotherapy that helps your immune system find and attack cancer cells. It's given as an infusion into a vein at a clinic.

Brand names:Imfinzi
Medication

What people taking Imfinzi (Durvalumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Imfinzi (Durvalumab) for Non-Small Cell Lung Cancer?

NameHow it went

About Imfinzi (Durvalumab)

What It's For

Durvalumab, sold as Imfinzi, is a cancer immunotherapy given by infusion into a vein. It is approved for adults with several cancers, and each approval is tied to a particular stage of disease and usually to particular partner treatments. In lung cancer, it is used in three main ways. For non-small cell lung cancer (NSCLC) that cannot be removed surgically, it is given on its own after chemotherapy and radiation have finished, as long as the cancer has not grown. For NSCLC that can be removed, it is combined with chemotherapy before surgery and continued alone afterward. For NSCLC that has spread, it is combined with chemotherapy and a second immunotherapy, tremelimumab (Imjudo). These NSCLC uses apply to tumors without known changes in the EGFR (epidermal growth factor receptor) or ALK (anaplastic lymphoma kinase) genes; tumors with those changes are usually treated with targeted drugs instead. In small cell lung cancer, it is given alone after chemoradiation for limited-stage disease, or with chemotherapy as first treatment for extensive-stage disease. Beyond the lungs, it is approved with chemotherapy for advanced bile duct and gallbladder cancers (biliary tract cancer); with a single dose of tremelimumab for liver cancer that cannot be removed; with chemotherapy for advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), a tumor feature confirmed by laboratory testing; for bladder cancer, either alongside BCG (a bladder-instilled immune treatment) for high-risk early disease or with chemotherapy around bladder removal surgery; and with FLOT, a four-drug chemotherapy combination (fluorouracil, leucovorin, oxaliplatin and docetaxel), around surgery for stomach cancer or cancer where the stomach meets the esophagus.

How It Works

Immune cells called T cells can recognize and kill cancer cells, but the body has built-in brakes, known as checkpoints, that keep the immune system from attacking healthy tissue. Many cancers exploit one of these brakes by displaying a protein called PD-L1 (programmed death-ligand 1). When PD-L1 connects with partner proteins on T cells, it switches the T cells down. Durvalumab is a laboratory-made antibody that attaches to PD-L1 and blocks that connection. With the brake released, T cells can become active against the tumor again. This is why it is called an immune checkpoint inhibitor. The same release explains its main risk: an immune system with fewer brakes can also attack healthy organs. Not everyone's cancer responds to it.

Dosage & Administration

Imfinzi is given in a cancer clinic or infusion center as an intravenous (IV) drip that usually takes about 60 minutes. Depending on the cancer and the regimen, infusions are every 2, 3 or 4 weeks. Most adults receive a fixed dose; people who weigh under 30 kg (about 66 pounds) receive a dose based on weight. When it is combined with chemotherapy, BCG or tremelimumab, it is usually given on the same day as those treatments. How long treatment lasts depends on the reason for using it. After chemoradiation for unresectable Stage III NSCLC, it is given for up to 12 months; for limited-stage small cell lung cancer, up to 24 months. Around surgery, it is given for a set number of cycles before and after the operation. In advanced cancers, it usually continues as long as it is working and side effects are manageable. Doses are not adjusted at home: the care team may pause or stop treatment based on side effects.

Side Effects

Tiredness, rash, itching, nausea, diarrhea, decreased appetite, muscle or joint aches and cough are among the most commonly reported problems. Many of these overlap with the effects of the chemotherapy or radiation it is combined with, so what someone notices depends heavily on the full regimen. After chest radiation, cough, shortness of breath and chest infections are especially common. The most important risk is an immune reaction against healthy organs. It can affect the lungs (pneumonitis), the bowel (colitis), the liver (hepatitis), the kidneys, the skin, the pancreas and hormone glands such as the thyroid, adrenal and pituitary glands. These reactions can appear at any time during treatment, and sometimes months after it ends. Some are severe or life-threatening, and getting treatment right away can keep a reaction from becoming more serious. Treatment usually means steroid medicines and a pause in infusions; when a hormone gland is affected, hormone replacement medicine may be needed. Contact the cancer care team right away, including through its after-hours line, for new or worsening cough, chest pain or shortness of breath; diarrhea, blood or mucus in the stool or severe abdominal pain; yellowing of the skin or eyes, dark urine, pain on the right side of the abdomen or easy bruising; a severe or blistering rash; or unusual fatigue, dizziness, headache, extreme thirst or frequent urination, which can signal a hormone problem. Chills, fever, flushing, itching or trouble breathing during or soon after an infusion should be reported immediately to the infusion staff or care team.

Interactions & Warnings

Before starting, tell the care team if you have an immune system condition such as Crohn's disease, ulcerative colitis or lupus; a nervous system condition such as myasthenia gravis; past radiation to the chest; an organ or tissue transplant, including a cornea transplant; or a past or planned stem cell transplant from a donor. Releasing the immune system's brakes can lead to rejection of a transplanted organ and to serious, sometimes fatal complications such as graft-versus-host disease after a donor stem cell transplant, and chest radiation raises the chance of lung inflammation. Durvalumab can harm a developing baby. People who could become pregnant are usually checked for pregnancy before treatment and advised to use effective contraception during treatment and for 3 months after the last dose; the chemotherapy given alongside it has its own requirements, which may differ. Breastfeeding is not recommended during treatment or for 3 months after the last dose. The medicines given with durvalumab each carry their own warnings, so the full regimen matters as much as durvalumab itself. Make sure every clinician you see knows you are receiving, or have recently received, immunotherapy, since its side effects can show up in any part of the body.

What to Expect

Infusion visits usually include blood tests, such as liver, kidney and thyroid checks, so the team can spot an immune reaction early, sometimes before it causes symptoms. Scans are repeated during treatment to see how the cancer is responding. Some people feel little difference day to day on durvalumab alone; others notice fatigue or skin changes. The benefit can be meaningful. In the main trial for unresectable Stage III NSCLC, about 43 of every 100 people who received durvalumab after chemoradiation were alive five years later, compared with about 33 of every 100 who received a placebo. Results differ by cancer and stage, and in many people the cancer still returns or grows. If an immune side effect develops, treatment is often paused while it is treated, and sometimes stopped for good. Because these effects can begin after the last infusion, it is worth staying alert to new symptoms and keeping follow-up appointments after treatment ends.

Questions to Ask Your Doctor

  1. 1.What is the goal of adding durvalumab for my type and stage of cancer, and how much benefit has been seen in people like me?
  2. 2.How long will I receive it, and what will be given alongside it?
  3. 3.Which symptoms should make me call right away, and how do I reach the team after hours?
  4. 4.Does my autoimmune condition, transplant history or other medicines change whether this treatment is safe for me?
  5. 5.How will we know whether it is working, and what are the options if it is not?

Last reviewed • Oct 2026

Educational content, not medical advice.